NKTR Q3 FY26 earnings call: key takeaways

• NKTR reported a net loss of $56 million, or $1.63 per share, for Q3 2026, which aligns with the consensus estimate of a loss of $2.16 per share (36:02)

Results vs expectations

What changed since last quarter

• The company raised its Phase 3 program for ResPeg, including a change in the Zenith AD2 study to include combination therapy with topical corticosteroids, based on regulatory feedback. (51:14)
• The timeline for the Zenith AA study was accelerated to start in December 2026, earlier than previously planned. (27:06)
• The company emphasized the potential for less frequent dosing of ResPeg based on off-treatment data, which could differentiate it in the market. (23:41)

What analysts pressed on

• Whether the off-treatment data for ResPeg will support less frequent dosing and long-term efficacy. (59:08)
• Concerns about the competitive landscape in atopic dermatitis and how ResPeg will differentiate itself from emerging therapies. (1:08:30)

In their words

• We anticipate our first top-line data readouts for the ectopic dermatitis studies will be in the summer of 2028. Howard Robin (11:47)
• RESPEG's novel TREG mechanism offers a critically important therapeutic modality for patients and one that is currently missing from the treatment armamentarium. Howard Robin (13:31)
• We now have a registrational program designed to support the broadest possible label for RESPEG at commercial launch, spanning adults and adolescents... Mary (18:10)
• If we see this level of maintenance of EZ75 at 12 months off-treatment or better, that would be an interesting finding. Mary (25:26)